Scientific Publications

The landmark research of BostonGene underscores the importance of combining innovative multi-platform analytics with cutting-edge software to improve patient outcomes. Explore our scientific publications to learn more.

A CD5 signature identifies diffuse large B-cell lymphomas (DLBCLs) sensitive to Bruton’s tyrosine kinase (BTK) inhibition
Cancer Research, 2023
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Nature Medicine, 2023
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma
Blood, 2023
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis
Therapeutic Advances in Medical Oncology, 2023
B cell-dependent subtypes and treatment-based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
FASEB, 2023
Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma
Science Translational Medicine, 2023
Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Blood, 2022
Integrated Genomic and Transcriptomic Analysis Provides Molecular Characterization of Distinct Clonal Evolution Pathways during Follicular Lymphoma Transformation
Blood, 2022
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
SpringerLink, 2022
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
Blood Journals, 2022
Contact us